Parabilis Medicines, Inc. (Ticker: PBLS) is an emerging company at the forefront of the telecommunications sector, dedicated to delivering innovative communication solutions tailored for both residential and commercial markets. The company leverages advanced technologies to enhance connectivity and customer experiences, positioning itself strategically for growth in the rapidly evolving digital landscape. With a strong focus on expanding its infrastructure and maintaining operational excellence, PBLS represents a compelling investment opportunity for institutional investors seeking to capitalize on the burgeoning demand for seamless communication services.
| Revenue (TTM) | 148,000 |
| Gross Profit (TTM) | $-12.95M |
| EBITDA | $-169.11M |
| Operating Margin | -34382.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $8.48 |
| Price-to-Book | 3.29 |
| Price-to-Sales (TTM) | 23813.54 |
| EV/Revenue | 16036.44 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $121.95M |
| Float | $82.07M |
| % Insiders | 7.03% |
| % Institutions | 83.38% |
Volatility is currently contracting
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced that Mathai Mammen, M.D.
Zolucatetide gives PBLS potential in desmoid tumors, but it also has other Wnt-driven indications that could grow its TAM over time. PBLS's PEDESTAL trial is now a clearer R&D path, as long as early responses are corroborated in that Phase 3 study for tumor control. Management's runway projection also suggests they have flexibility and should be able to reach pivotal milestones with Zolucatetide.
Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript
Parabilis Medicines, Inc. is rated a speculative Buy due to its innovative peptide platform and strong rare-disease oncology pipeline. Lead asset zolucatetide (zolu) shows robust early efficacy in desmoid tumors and craniopharyngioma, with favorable safety and FDA Orphan/Fast Track designations. PBLS benefits from a $125M upfront/Regeneron partnership, $1.1B cash, and a projected cash runway into 2030, minimizing near-term dilution risk.
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President and Chief Executive Officer Mathai Mammen, M.D.
CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L.
Parabilis Medicines (PBLS) leverages rare, genetically simple tumors to validate its Helicon platform, aiming for broader oncology applications. PBLS holds $1.1 billion in cash, providing a runway into 2030 to support clinical trials, platform expansion, and reduce financing risk. Early zolucatetide data in desmoid tumors show 100% tumor reduction and 74% objective response, with a favorable safety profile versus competitors.
Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PBLS and any ticker you trade — then tracks every position and per-strategy win rate.
